CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Conditions: Intermediate Stage of Hepatocellular Carcinoma; Hepatocellular Carcinoma Interventions: Drug: Durvalumab; Drug: Tremelimumab 300 mg; Drug: Tremelimumab 75 mg Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Research